Get the Latest Stryker Stock Quote and Financial Data

To get the latest Stryker stock quote and financial data, you can visit the company's investor relations website. This website is a great resource for staying up-to-date on Stryker's financial performance.

Stryker's stock is listed on the New York Stock Exchange under the ticker symbol SYK. You can also find Stryker's financial data on websites like Yahoo Finance or Google Finance.

Stryker's financial data includes information on revenue, net income, and earnings per share. This data is typically reported on a quarterly and annual basis.

Stryker's revenue in 2023 was a staggering $20.50 billion, a significant increase of 11.11% compared to the previous year's $18.45 billion.

Their earnings also saw a substantial jump, rising by 34.22% to $3.17 billion.

Stryker's financial performance is a testament to their steady growth and success.

Here's a breakdown of their key financial metrics:

Their strong financial performance has investors taking notice, with many eyeing Stryker Corporation (SYK) closely for future growth opportunities.

Stryker is a medical technology company that operates in a competitive field.

The company's valuation is assessed at 1 out of 6, indicating a potentially overvalued stock.

Stryker's past performance has been strong, with a score of 5 out of 6, suggesting a consistent track record of success.

The company's financial health is rated 3 out of 6, which may indicate some areas for improvement.

Here's a breakdown of Stryker's fundamental analysis scores:

Analysts are overwhelmingly bullish on Stryker stock, with an average rating of "Buy" from 20 analysts. This suggests a high level of confidence in the company's future performance.

The 12-month stock price forecast is $408.21, representing a 2.82% increase from the latest price.

The majority of analysts have maintained their "Buy" recommendations over the past three months, with 17 analysts currently recommending a "Buy" compared to 18 three months ago.

Here's a breakdown of the analysts' recommendations:

The analysts' consensus is clear: Stryker stock is a strong buy, and it's expected to continue its upward trend in the coming months.

Stryker Corporation has made a significant move in the medical technology industry. Stryker agreed to acquire Inari Medical Inc. for $80 per share in cash.

The deal is valued at approximately $4.9 billion, making it a substantial investment for Stryker. Stryker will acquire all of Inari Medical's shares.

Inari Medical makes mechanical thrombectomy solutions designed to treat peripheral vascular diseases. Stryker said the deal would be complementary to its neurovascular business.

Stryker Corporation is a global leader in medical technologies.

Stryker Corporation is a global leader in medical devices, with strong growth prospects driven by an aging population and technological advancements.

The company has a robust track record of double-digit earnings growth, making it an attractive investment opportunity for those looking to capitalize on the healthcare industry's ongoing expansion.

Investors should own Stryker stock due to its high quality MedTech name and promising future prospects.

Stryker's leadership in the medical device market is a key factor in its success, with a diverse portfolio of products that cater to various healthcare needs.

The company's strong financial performance has led to a significant increase in its stock price over the years, making it a valuable addition to any investment portfolio.

Aging population and technological advancements are driving the growth of the medical device industry, and Stryker is well-positioned to benefit from these trends.

Stryker declares a quarterly dividend of $0.84 per share, payable on January 31, 2025 to shareholders.

This is a significant payment for investors, and it's great to see companies like Stryker rewarding their shareholders with a steady stream of income.

Stryker's Board of Directors has declared this dividend, showing confidence in the company's financial health and future prospects.

The company's steady earnings growth, margin improvements, and strategic acquisitions are all contributing factors to this decision.

Here are some key details about Stryker's dividend and earnings:

With a one-year price target 12.66% higher, Stryker's stock is looking strong, and investors would do well to keep an eye on this company's progress.

Stryker has a history of acquiring other firms to boost its growth. The company has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry.

Stryker's acquisition strategy has been successful, with the company experiencing double-digit growth as a result. This growth is a testament to the company's ability to integrate new businesses and expand its offerings.

Stryker has completed several notable acquisitions, including the purchase of Vertos Medical Inc. in 2024.

A unique perspective: Stock Symbol for Gillette

Stryker has been on an acquisition spree, expanding its offerings in the medical device industry.

Stryker's acquisition strategy has been successful, with the company rising to become the third-largest U.S. firm in the healthcare equipment and supplies industry.

The company has acquired several firms to boost its portfolio, including Vertos Medical Inc. and care.ai, both of which expand its interventional pain management solutions.

Stryker's acquisitions have been completed in recent years, with the company announcing the addition of new products to its Foot & Ankle portfolio in 2024.

Discover more: Black Rifle Coffee Stock Symbol

The company's acquisition of Inari Medical in 2025 is valued at $4.9 billion, and will be complementary to its neurovascular business.

Stryker's acquisition strategy has been focused on expanding its offerings in the medical device industry, with a focus on interventional pain management solutions and neurovascular business.

The company's acquisitions have been completed through definitive agreements, with the most recent being the acquisition of Inari Medical in 2025.

The company has a rich 37-year history, with its first acquisition taking place in 1985.

In 1992, the company acquired a rival business, expanding its product line and customer base.

This acquisition marked a significant turning point in the company's history, as it allowed the company to enter new markets and increase its competitiveness.

The company continued to grow and evolve, with a major restructuring in 2001 that led to significant cost savings and improved efficiency.

By 2007, the company had expanded its product line to include a range of new offerings, increasing its revenue by 25% that year.

Recommended read: New Relic Stock Symbol

The company's acquisition strategy continued to drive growth, with a major acquisition in 2010 that brought in significant new technology and expertise.

In 2015, the company celebrated its 30th anniversary, marking a major milestone in its history.

The company has continued to grow and evolve, with a major expansion into new markets in 2020.

Related reading: Paypal Is a Profitable Growth Stock with New Management